Canaccord Genuity Morning Coffee on Arena Pharma. (ARNA): Does This Mean I Can Keep Eating Super-Sized Double Big Mac Meals?
Tweet Send to a FriendGet Alerts ARNA Hot Sheet
Price: $7.98 -0.25%
Rating Summary:
3 Buy, 8 Hold, 5 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Rating Summary:
3 Buy, 8 Hold, 5 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Trade ARNA Now!
Canaccord Genuity Morning Coffee on Arena Pharma. (Nasdaq: ARNA): Does this mean I can keep eating Super-Sized Double Big Mac meals?
Shares of Arena Pharmaceuticals gained almost 30% after the company announced that the U.S. Food and Drug Administration (FDA) have approved the company’s anti-obesity drug Lorcaserin. The FDA directed a study which evaluated 604 obese and overweight participants with type 2 diabetes in a doubleblind placebo-controlled randomized trial over a one-year treatment period. Although all participants received systematic lifestyle change counseling, those on the medication lost 4.5 – 5.0% of their initial bodyweight compared to a loss of 1.5% by patients on the inactive placebo. Jack Lief, Arena's President and Chief Executive Officer noted, "The FDA approval of our drug is an important development for patients who struggle with obesity or are overweight with co-morbidities and need help with chronic weight management beyond diet and exercise." The approval of Lorcaserin marks the first time in over 10 years that the FDA has approved an anti-obesity drug. Wall Street analyst expects Lorcaserin to have annual sales of $1.4 billion by 2020. Shares of Vivus (Nasdaq: VVUS) and Orexigen (Nasdaq: OREX) also popped on the news, as both companies are also developing antiobesity drugs.
To see more ratings on ARNA, Click Here
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Shares of Arena Pharmaceuticals gained almost 30% after the company announced that the U.S. Food and Drug Administration (FDA) have approved the company’s anti-obesity drug Lorcaserin. The FDA directed a study which evaluated 604 obese and overweight participants with type 2 diabetes in a doubleblind placebo-controlled randomized trial over a one-year treatment period. Although all participants received systematic lifestyle change counseling, those on the medication lost 4.5 – 5.0% of their initial bodyweight compared to a loss of 1.5% by patients on the inactive placebo. Jack Lief, Arena's President and Chief Executive Officer noted, "The FDA approval of our drug is an important development for patients who struggle with obesity or are overweight with co-morbidities and need help with chronic weight management beyond diet and exercise." The approval of Lorcaserin marks the first time in over 10 years that the FDA has approved an anti-obesity drug. Wall Street analyst expects Lorcaserin to have annual sales of $1.4 billion by 2020. Shares of Vivus (Nasdaq: VVUS) and Orexigen (Nasdaq: OREX) also popped on the news, as both companies are also developing antiobesity drugs.
To see more ratings on ARNA, Click Here
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Morgan Stanley Says Tesla (TSLA) 'Top Pick in U.S. Autos'
- Wells Fargo Upgrades Rosetta Resources (ROSE) to Outperform, Shares Attractive
- Jefferies Buyers of Jack In The Box (JACK) on Solid Results
Create E-mail Alert Related Categories
Analyst Comments, FDARelated Entities
Canaccord Genuity
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
